December 20, 2022 – Abbott announced the FDA approval of the company’s Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott’s proprietary low-dose BurstDR™ stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.
Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted a smaller implant for comfort while reducing the need to charge the device daily or weekly. With patient needs front of mind, Abbott created Eterna to be recharged less than five times a year under normal use, making it the lowest recharge burden platform on the market.
Key features include:
- Smallest device: Designed with daily comfort in mind6 the Eterna SCS system is the smallest implantable, rechargeable spinal cord stimulator on the market.
- Clinically proven therapy: The Eterna SCS system features Abbott’s proprietary BurstDR stimulation, which mimics natural firing patterns found in the brain to deliver superior pain relief. BurstDR stimulation is preferred to traditional “tingling” tonic stimulation by 87% of patients.
- Lowest recharging requirements: Paired with Abbott’s new Xtend™ energy technology, Eterna optimizes the patient charging experience, requiring as few as five recharges per year under standard use from a wireless charger.
- MRI capabilities: Eterna uses Abbott’s TotalScan™ MRI technology, which allows for full-body MRI scans – a critical need of chronic pain patients who require accessibility to improved diagnostics and healthcare.
- Upgradable platform: As Abbott continues to make advancements in SCS therapy, the Eterna SCS system can adapt to future innovations without replacing the implant.
- iPhone integration: Abbott’s patient-focused mobile app supports real-time battery life and charging status updates of the Eterna SCS system on a personal or Abbott-provided Apple device.
Abbott’s portfolio of neuromodulation devices also includes Proclaim™ XR, the recharge-free SCS system, and Proclaim Plus featuring FlexBurst360™, the SCS system that offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person’s therapeutic needs evolve. All use the clinically proven low-dose BurstDR stimulation therapy.